Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18 years.~* Performance status ≤ 2 according to the WHO criteria.~* Life expectancy\> 3 months.~* Patient in hormonal blockade based on surgical castration by orchiectomy or pulpectomy, medical or agonist or antagonists of LHRH associated or not with anti-androgens or any other treatment that blocks the fraction of non-gonadal testosterone, resulting in a testosterone \<0.5 ng / mL.~* Patient with adenocarcinoma of the prostate and histologically proven metastatic castration-resistant stage, defined by: objective progression of at least one measurable tumor target and / or assessable by RECIST, and / or increase in PSA (rising PSA).~* Satisfactory biological functions (renal, hepatic and hematologic)~* Patient who signed the consent for participation before entering the study.~* Affiliation to a social security scheme (or be the beneficiary of such a plan) under the terms of the law of 9 August 2004.~Exclusion Criteria:~* Age \<18 years.~* Performance status\> 2 according to the WHO criteria.~* Patient deprived of liberty or under guardianship, patient with (the) condition (s) psychological, family, social or geographic may interfere with the proper conduct of the study.~* Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer considered cured.~* Patient with brain metastases at initial assessment.~* Patient with another pathology deemed incompatible with the inclusion in the protocol.~* Laboratory tests inadequate.~* History of malabsorption syndrome or extensive resection of the upper digestive tract.~* Uncontrolled intercurrent infection.~* Pathology autoimmune and / or chronic active inflammation.~* peripheral neuropathy grade 2 according to the criteria of the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0).~* History of allergy to polysorbate 80.~* Treatment with nonsteroidal anti-inflammatory and / or cyclooxygenase-2 dated within three weeks.~* Concomitant with a drug test or participation in another clinical trial within \<30 days treatment.~* Regular Taking dietary supplements.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Curcumin (Type: EXPERIMENTAL): curcumine capsule
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).